Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Table 1

Demographic and baseline characteristics of the patients.

Characteristics	Treatment group; (𝑛=136)	Control group; (𝑛=135)	𝑃 value
Age (years)^†	33.5±10.1	32.8±9.1	0.346
Male	104 (76.5)	104 (77.0)	1.000
Height (cm)^†	169.1±6.6	168.9±6.1	0.516
Weight (kg)^†	65.0±10.0	65.5±10.7	0.824
Body mass index (kg/m^2)^†	22.7±2.8	22.9±3.0	0.775
Course of illness (years)^†	7.7±6.1	6.9±5.8	0.450
HBV DNA (lgcopies/mL)^†	7.2±1.2	7.3±1.4	0.456
Grade of necroinflammatory*			0.600
G2	28 (68.3)	29 (74.4)
G3	10 (24.4)	9 (23.1)
G4	3 (7.3)	1 (2.6)
Stage of fibrosis*			0.621
S0	0 (0.0)	1 (2.6)
S1	12 (29.3)	7 (17.9)
S2	17 (41.5)	19 (48.7)
S3	9 (22.0)	10 (25.6)
S4	3 (7.3)	2 (5.1)
Prior resistance by genotypic analysis*	0 (0)	0 (0)	1.000

∗A total of 80 patients had adequate baseline and liver-biopsy specimens at week 52 (41 patients in treatment group and 39 in control group). Values in parentheses are percentages unless indicated otherwise; ^†value was presented as mean ± standard deviation.